Skip to main content
Top
Published in: Journal of General Internal Medicine 10/2017

01-10-2017 | Original Research

Incidence and Predictors of Repeat Bone Mineral Densitometry: A Longitudinal Cohort Study

Authors: Emily C. White VanGompel, MD, MPH, Peter Franks, MD, John A. Robbins, MD, MHS, Joshua J. Fenton, MD, MPH

Published in: Journal of General Internal Medicine | Issue 10/2017

Login to get access

Abstract

Background

Existing guidelines for repeat screening and treatment monitoring intervals regarding the use of dual-energy x-ray absorptiometry (DXA) scans are conflicting or lacking. The Choosing Wisely campaign recommends against repeating DXA scans within 2 years of initial screening. It is unclear how frequently physicians order repeat scans and what clinical factors contribute to their use.

Objective

To estimate cumulative incidence and predictors of repeat DXA for screening or treatment monitoring in a regional health system.

Design

Retrospective longitudinal cohort study

Participants

A total of 5992 women aged 40–84 years who received initial DXA screening from 2006 to 2011 within a regional health system in Sacramento, CA.

Main Measures

Two- and five-year cumulative incidence and hazard rations (HR) of repeat DXA by initial screening result (classified into three groups: low or high risk of progression to osteoporosis, or osteoporosis) and whether women were prescribed osteoporosis drugs after initial DXA.

Key Results

Among women not treated after initial DXA, 2-year cumulative incidence for low-risk, high-risk, and osteoporotic women was 8.0%, 13.8%, and 19.6%, respectively, increasing to 42.9%, 60.4%, and 57.4% by 5 years after initial screening. For treated women, median time to repeat DXA was over 3 years for all groups. Relative to women with low-risk initial DXA, high-risk initial DXA significantly predicted repeat screening for untreated women [adjusted HR 1.67 (95% CI 1.40–2.00)] but not within the treated group [HR 1.09 (95% CI 0.91–1.30)].

Conclusions

Repeat DXA screening was common in women both at low and high risk of progression to osteoporosis, with a substantial proportion of women receiving repeat scans within 2 years of initial screening. Conversely, only 60% of those at high-risk of progression to osteoporosis were re-screened within 5 years. Interventions are needed to help clinicians make higher-value decisions regarding repeat use of DXA scans.
Literature
1.
go back to reference U.S. Preventive Services Task Force. Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2011;154:356–364.CrossRef U.S. Preventive Services Task Force. Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2011;154:356–364.CrossRef
2.
go back to reference Morris CA, Cabral D, Cheng H, et al. Patterns of Bone Mineral Density Testing: Current Guidelines, Testing Rates, and Interventions. J Gen Intern Med. 2004;19(7):783–790.CrossRefPubMedPubMedCentral Morris CA, Cabral D, Cheng H, et al. Patterns of Bone Mineral Density Testing: Current Guidelines, Testing Rates, and Interventions. J Gen Intern Med. 2004;19(7):783–790.CrossRefPubMedPubMedCentral
3.
go back to reference Lenchik L, Kiebzak GM, Blunt BA. What is the role of serial bone mineral density measurements in patient management? J Clin Densitom. 2002;5 Suppl:S29–38.CrossRefPubMed Lenchik L, Kiebzak GM, Blunt BA. What is the role of serial bone mineral density measurements in patient management? J Clin Densitom. 2002;5 Suppl:S29–38.CrossRefPubMed
4.
go back to reference North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(1):25–54.CrossRef North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(1):25–54.CrossRef
5.
go back to reference Bell KJ, Hayen A, Macaskill P, et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ. 2009;338:b2266.CrossRefPubMedPubMedCentral Bell KJ, Hayen A, Macaskill P, et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ. 2009;338:b2266.CrossRefPubMedPubMedCentral
7.
go back to reference Watts NB, Lewiecki EM, Bonnick SL, et al. Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res. 2009;24(10):1643–1646.CrossRefPubMed Watts NB, Lewiecki EM, Bonnick SL, et al. Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res. 2009;24(10):1643–1646.CrossRefPubMed
8.
go back to reference Gourlay ML, Fine JP, Preisser JS, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366(3):225–233.CrossRefPubMedPubMedCentral Gourlay ML, Fine JP, Preisser JS, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366(3):225–233.CrossRefPubMedPubMedCentral
9.
go back to reference Hillier TA, Stone KL, Bauer DC, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167(2):155–160.CrossRefPubMed Hillier TA, Stone KL, Bauer DC, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167(2):155–160.CrossRefPubMed
10.
go back to reference Berry SD, Samelson EJ, Pencina MJ, et al. Repeat bone mineral density screening and prediction of hip and major osteoporotic fracture. JAMA. 2013;310(12):1256–1262.CrossRefPubMedPubMedCentral Berry SD, Samelson EJ, Pencina MJ, et al. Repeat bone mineral density screening and prediction of hip and major osteoporotic fracture. JAMA. 2013;310(12):1256–1262.CrossRefPubMedPubMedCentral
11.
go back to reference Yazdany J, Schmajuk G, Robbins M, et al. Choosing wisely: the American College of Rheumatology’s Top 5 list of things physicians and patients should question. Arthritis Care Res. 2013;65(3):329–339.CrossRef Yazdany J, Schmajuk G, Robbins M, et al. Choosing wisely: the American College of Rheumatology’s Top 5 list of things physicians and patients should question. Arthritis Care Res. 2013;65(3):329–339.CrossRef
12.
go back to reference Morden NE, Schpero WL, Zaha R, Sequist TD, Colla CH. Overuse of short-interval bone densitometry: assessing rates of low-value care. Osteoporos Int. 2014;25(9):2307–2311.CrossRefPubMedPubMedCentral Morden NE, Schpero WL, Zaha R, Sequist TD, Colla CH. Overuse of short-interval bone densitometry: assessing rates of low-value care. Osteoporos Int. 2014;25(9):2307–2311.CrossRefPubMedPubMedCentral
13.
go back to reference Amarnath AL, Franks P, Robbins JA, Xing G, Fenton JJ. Underuse and Overuse of Osteoporosis Screening in a Regional Health System: a Retrospective Cohort Study. J Gen Intern Med. 2015;30(12):1733–1740.CrossRefPubMedPubMedCentral Amarnath AL, Franks P, Robbins JA, Xing G, Fenton JJ. Underuse and Overuse of Osteoporosis Screening in a Regional Health System: a Retrospective Cohort Study. J Gen Intern Med. 2015;30(12):1733–1740.CrossRefPubMedPubMedCentral
14.
go back to reference Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom. 2013;16(4):455–466.CrossRefPubMed Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom. 2013;16(4):455–466.CrossRefPubMed
16.
go back to reference Wang PS, Walker A, Tsuang M, Orav EJ, Levin R, Avorn J. Strategies for improving comorbidity measures based on Medicare and Medicaid claims data. J Clin Epidemiol. 2000;53(6):571–578.CrossRefPubMed Wang PS, Walker A, Tsuang M, Orav EJ, Levin R, Avorn J. Strategies for improving comorbidity measures based on Medicare and Medicaid claims data. J Clin Epidemiol. 2000;53(6):571–578.CrossRefPubMed
17.
go back to reference Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16 Suppl 3:1–37.CrossRefPubMedPubMedCentral Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16 Suppl 3:1–37.CrossRefPubMedPubMedCentral
18.
go back to reference Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int. 2005;16(7):842–848.CrossRefPubMed Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int. 2005;16(7):842–848.CrossRefPubMed
19.
go back to reference Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004;7(3):255–261.CrossRefPubMed Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004;7(3):255–261.CrossRefPubMed
20.
go back to reference Nelson HD, Morris CD, Kraemer DF, et al. Osteoporosis in postmenopausal women: diagnosis and monitoring. Evid Rep Technol Assess (Summ). 2001(28):1–2. Nelson HD, Morris CD, Kraemer DF, et al. Osteoporosis in postmenopausal women: diagnosis and monitoring. Evid Rep Technol Assess (Summ). 2001(28):1–2.
Metadata
Title
Incidence and Predictors of Repeat Bone Mineral Densitometry: A Longitudinal Cohort Study
Authors
Emily C. White VanGompel, MD, MPH
Peter Franks, MD
John A. Robbins, MD, MHS
Joshua J. Fenton, MD, MPH
Publication date
01-10-2017
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 10/2017
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-017-4094-y

Other articles of this Issue 10/2017

Journal of General Internal Medicine 10/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.